Your browser doesn't support javascript.
loading
Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib.
Saiag, Philippe; Robert, Caroline; Grob, Jean-Jacques; Mortier, Laurent; Dereure, Olivier; Lebbe, Céleste; Mansard, Sandrine; Grange, Florent; Neidhardt, Eve-Marie; Lesimple, Thierry; Machet, Laurent; Bedane, Christophe; Maillard, Hervé; Dalac-Rat, Sophie; Nardin, Charlée; Szenik, Alexandra; Denden, Amine; Dutriaux, Caroline.
Affiliation
  • Saiag P; University of Paris-Saclay, UVSQ, EA4340, Boulogne-Billancourt 92100, France; APHP Hôpital Ambroise Paré, Department of Dermatology, F 92100, Boulogne-Billancourt, France. Electronic address: philippe.saiag@uvsq.fr.
  • Robert C; Department of Dermatology, Institut Gustave Roussy, Villejuif, France.
  • Grob JJ; Department of Dermatology, Aix-Marseille University, APHM, University Hospital Timone, Marseille, France.
  • Mortier L; Université de Lille, INSERM U 1189, Service de Dermatologie, CHU Lille, Lille 59000, France.
  • Dereure O; Department of Dermatology, CHU Montpellier, Montpellier, France.
  • Lebbe C; Université de Paris, INSERM U976, Team 1, HIPI, Paris 75010, France; AP-HP Hopital Saint Louis, Service de Dermatologie, Paris 75010, France.
  • Mansard S; Department of Dermatology, CHU Estaing, Clermont-Ferrand, France.
  • Grange F; Department of Dermatology, CHU Reims, Reims, France.
  • Neidhardt EM; Department of Medical Oncology, Centre Léon Bérard, Lyon, France.
  • Lesimple T; Department of Medical Oncology, Eugene Marquis Center, Rennes, France.
  • Machet L; Department of Dermatology, CHRU de Tours et Université François Rabelais de Tours, Tours, France.
  • Bedane C; Department of Dermatology, CHU Limoges, Limoges, France.
  • Maillard H; Department of Dermatology, CHRU de Tours et Université François Rabelais de Tours, Tours, France.
  • Dalac-Rat S; Department of Dermatology, CHU Le Mans, Le Mans, France.
  • Nardin C; Department of Dermatology, CHU Dijon, Dijon, France.
  • Szenik A; Department of Dermatology, CHU de Besançon, Besançon, France.
  • Denden A; Department of Medical Oncology, Novartis Pharma S.A.S.-France, Rueil-Malmaison, France.
  • Dutriaux C; Department of Dermatology, CHU Bordeaux Hôpital St. André, Bordeaux, France.
Eur J Cancer ; 154: 57-65, 2021 09.
Article in En | MEDLINE | ID: mdl-34243078
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Proto-Oncogene Proteins B-raf / Melanoma / Mutation Type of study: Clinical_trials / Observational_studies / Prognostic_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Eur J Cancer Year: 2021 Document type: Article Country of publication: Reino Unido
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Proto-Oncogene Proteins B-raf / Melanoma / Mutation Type of study: Clinical_trials / Observational_studies / Prognostic_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Eur J Cancer Year: 2021 Document type: Article Country of publication: Reino Unido